StreetInsider.com News Articles

Form 8-K LIPELLA PHARMACEUTICALS For: Mar 30

Tue, 31 Mar 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260331/26244421.html

Form 8-K LIPELLA PHARMACEUTICALS For: Mar 30

Tue, 31 Mar 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260331/26244421.html

Form 8-K LIPELLA PHARMACEUTICALS For: Feb 03

Wed, 04 Feb 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260204/25947322.html

Form 8-K LIPELLA PHARMACEUTICALS For: Feb 03

Wed, 04 Feb 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260204/25947322.html

Form 10-Q LIPELLA PHARMACEUTICALS For: Sep 30

Fri, 14 Nov 2025 16:47:00 -0400

si-local-file:///var/storage/secattach/20251114/25618673.html

Form 10-Q LIPELLA PHARMACEUTICALS For: Sep 30

Fri, 14 Nov 2025 16:47:00 -0400

si-local-file:///var/storage/secattach/20251114/25618673.html

Form 8-K LIPELLA PHARMACEUTICALS For: Oct 20

Tue, 21 Oct 2025 16:18:00 -0400

si-local-file:///var/storage/secattach/20251021/25482941.html

Form 8-K LIPELLA PHARMACEUTICALS For: Oct 20

Tue, 21 Oct 2025 16:18:00 -0400

si-local-file:///var/storage/secattach/20251021/25482941.html

Form 8-K LIPELLA PHARMACEUTICALS For: Oct 03

Thu, 09 Oct 2025 17:01:00 -0400

si-local-file:///var/storage/secattach/20251009/25441486.html

Form 8-K LIPELLA PHARMACEUTICALS For: Oct 03

Thu, 09 Oct 2025 17:01:00 -0400

si-local-file:///var/storage/secattach/20251009/25441486.html

Form 25-NSE LIPELLA PHARMACEUTICALS Filed by: Nasdaq Stock Market LLC

Mon, 06 Oct 2025 12:28:00 -0400

si-local-file:///var/storage/secattach/20251006/25423637.html

Form 25-NSE LIPELLA PHARMACEUTICALS Filed by: Nasdaq Stock Market LLC

Mon, 06 Oct 2025 12:28:00 -0400

si-local-file:///var/storage/secattach/20251006/25423637.html

Form 8-K LIPELLA PHARMACEUTICALS For: Sep 18

Thu, 18 Sep 2025 08:02:00 -0400

si-local-file:///var/storage/secattach/20250918/25348791.html

Form 8-K LIPELLA PHARMACEUTICALS For: Sep 18

Thu, 18 Sep 2025 08:02:00 -0400

si-local-file:///var/storage/secattach/20250918/25348791.html

Lipella reports positive phase 2a results for oral lichen planus drug

Thu, 18 Sep 2025 08:00:40 -0400

Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) announced results from its phase 2a study of LP-10, a liposomal tacrolimus oral rinse for treating oral lichen planus, a chronic inflammatory condition affecting an estimated 6 million Americans with no approved treatments.

The multicenter study enrolled 27 adults with biopsy-confirmed symptomatic oral lichen planus across five U.S. clinical sites. All patients completed the 4-week treatment course with no serious adverse events reported. The study tested three dose levels of LP-10 administered as a 3-minute oral rinse twice daily.

All three dose groups demonstrated statistically significant improvements at week 4 across secondary efficacy endpoints. Investigator Global Assessment

Lipella reports positive phase 2a results for oral lichen planus drug

Thu, 18 Sep 2025 08:00:40 -0400

All three dose groups demonstrated statistically significant improvements at week 4 across secondary efficacy endpoints. Investigator Global Assessment

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

Thu, 18 Sep 2025 08:00:00 -0400

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile
Statistically significant improvements achieved across all efficacy endpoints at the 4-week timepoint
Preparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration

PITTSBURGH, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq : LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced positive final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in patients with symptomatic oral lichen planus

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

Thu, 18 Sep 2025 08:00:00 -0400

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile
Statistically significant improvements achieved across all efficacy endpoints at the 4-week timepoint
Preparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

Thu, 18 Sep 2025 08:00:00 -0400

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile
Statistically significant improvements achieved across all efficacy endpoints at the 4-week timepoint
Preparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

Thu, 18 Sep 2025 08:00:00 -0400

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile
Statistically significant improvements achieved across all efficacy endpoints at the 4-week timepoint
Preparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration

Life Science Virtual Investor Forum Agenda Announced for September 18th